Abstract
Critical knowledge gaps regarding infection with Mycobacterium ulcerans, the cause of Buruli ulcer (BU), have impeded development of new therapeutic approaches and vaccines for prevention of this neglected tropical disease. Here, we review the current understanding of host–pathogen interactions and correlates of immune protection to explore the case for establishing a controlled human infection model of M. ulcerans infection. We also summarise the overarching safety considerations and present a rationale for selecting a suitable challenge strain.
Funder
National Health and Medical Research Council
Publisher
Public Library of Science (PLoS)
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health
Reference94 articles.
1. A new mycobacterial infection in man;P MacCallum;J Pathol Bacteriol,1948
2. Study of a mycobacterium causing skin ulceration in Uganda.;J Clancey;Ann De La Société Belge De Médecine Tropicale,1962
3. The changing epidemiology worldwide of Mycobacterium ulcerans;DP O’Brien;Epidemiol Infect,2019
4. Neglected tropical diseases: progress towards addressing the chronic pandemic;DH Molyneux;Lancet,2017
5. Emergence of Buruli ulcer disease in the Daloa region of Cote D’Ivoire;BJ Marston;Am J Trop Med Hyg,1995